StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Arrowhead Pharmaceuticals's EV/EBITDA was 28.3× on Apr 30, 2026, against 105.7× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202628.3×−39.1
2025Dec 31, 202567.4×−681.3
2020May 29, 2020748.7×+657.4
2019Dec 31, 201991.3×–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?